Physical ability: What is important to you? Take part

Published:

Updated:

Are you interested in participating in two telephone/video interviews to discuss your experience of Spinal Muscular Atrophy (SMA) and to help us understand what an important change in physical ability would be?

We are looking for:

Individuals living with SMA

·         Aged 12-30 years old from the United Kingdom (UK) and United States (US)

·         With a confirmed diagnosis of SMA, either ambulant (able to walk) or non-ambulant (unable to walk)

Caregivers of individuals living with SMA

·         Aged 18 years or over from the UK and US

·         Care for an individual who is 2-30 years old with a confirmed diagnosis of SMA, either ambulant (able to walk) or non-ambulant (unable to walk)

Are you interested in taking part in two telephone/video interviews to discuss your experience of Spinal Muscular Atrophy (SMA) and to help us to understand what an important change in physical ability would be?

The interviews:

Before the interviews you will be asked to fill in a form with some questions about yourself and a questionnaire used by doctors to assess physical ability in SMA. The aim of the interviews is to understand what changes on the questionnaire would be important  and how these changes would impact daily life.

 You will be invited to take part in two 60-minute interviews (with breaks as needed), approximately 3-4 months apart.

You will receive £100/$110 for each interview you participate in.

If you are interested or would like further information, please contact:

Email: sophie.wallace@adelphivalues.com

Telephone: +44 1625 57 8200

Link to study invitation letter

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more